Who can stand up when the four major vaccine companies take part in the $5 billion market and the vaccine storm reappears?

On July 15, the State Drug Administration issued a circular, found that Changchun Changsheng Biotech Co., Ltd.'s frozen-dried human rabies vaccine production record fraud and other serious violations of the "Drug Production Quality Management Code" behavior, has asked the Jilin Food and Drug Administration to withdraw the company's "Drug GMP Certificate", ordered to stop the production of rabies vaccine.
After the "Shandong Vaccine Incident" in 2016, the vaccine industry fell into a downturn, a number of vaccine companies in the New Deal under the requirements of continuous adjustment of strategy, after several twists and turns finally returned to the previous level, Changsheng, Zhifei, Chengda Bio, Kantai Bio four vaccine giants in 2017 have ushered in a substantial increase in performance.
This rabies vaccine wave, directly affected by the long-term organisms, it is understood that the company for all batches of freeze-dried human rabies vaccine (vero cells) within the validity period of the full implementation of the recall, is expected to reduce the company's first half of 2018 operating income of about 200 million yuan, the product shutdown on the company's production, operations have a greater impact, is expected to reduce the second half of 2018 operating income of about 540 million yuan.
2017, the big four vaccine giants have total revenues of more than 5 billion yuan, what are their fist products? What is the potential of these products?Perennia: Class II vaccines account for more than 90% of revenue, rabies vaccine crisis
Changchun Changsheng is a wholly owned subsidiary of Perennia Biosysm and a major source of sales revenue for Perennia Bio-Vaccines. Changsheng Biology mentioned in its annual report that the willingness of the age-appropriate population to take the initiative to vaccinate after the "Shandong vaccine incident" has declined, while the state has revised the Regulations on the Circulation of Vaccines and the Administration of Vaccinations, which have been affected by the convergence and implementation of the New Deal and other factors, which have also had a significant negative impact on the company's product sales in the short term. Changsheng Bio through product quality improvement, expand the market, optimize the construction of sales network, quickly adapt to the new changes in the market after the New Deal vaccine, the second half of 2016 the company's sales of major products gradually recovered. The company's first-class vaccine products sales are relatively stable, the second-class vaccine products in the freeze-dried human rabies vaccine (Vero cells) is the company's main sales varieties, due to strong rigid demand for products, in the vaccine industry as a whole affected by the background, the company still achieved a more optimistic operating performance. In 2016, sales of long-term bio-vaccines reached 1.015 billion yuan, an increase of 28.52% year-on-year.
In 2017, Changsheng Bio actively adapts to the relevant regulatory requirements of the new vaccine management policy, strengthens sales management, actively promotes the integration of the new promotion service team and the construction of sales channels, and effectively promotes the rapid growth of the company's performance by strengthening academic promotion conferences and company research, strengthening links with disease prevention and control agencies at all levels, and enhancing the brand influence of the company's vaccine products. Sales of long-term bio-vaccines reached 1,539 million yuan in 2017, up 51.67 percent year-on-year.
from the data point of view, so far, changsheng organisms have been successfully out of the "Shandong vaccine event" impact, and the vaccine rigid demand is strong advantage, the performance has been rapid growth. According to the 2017 Annual Report, the operating income of Class II vaccines accounts for 91.68 percent of the total operating income of Perpeothytic Biology, and the discontinued rabies vaccine is the company's main sales of Class II vaccines. On July 18, Changsheng Bio issued an unusually volatile stock trading announcement, after which the company implemented a recall of all batches of freeze-dried human rabies vaccine (vero cells) valid for the period, which is expected to reduce the company's operating income of about 200 million yuan in the first half of 2018 and net profit of about 140 million yuan. The company's first-half net profit growth is expected to be adjusted to -20% to 20%, about 211 million to 317 million yuan. The production and operation of the freeze-dried human rabies vaccine (vero cells) will have a greater impact on the company's production and operation, and is expected to reduce operating income by about 540 million yuan in the second half of 2018.Zhifei Bio: Independent products and agent products two-wheel drive
Zhifei Bio's business income mainly comes from the sale of second-class vaccines. 2016 by the "Shandong vaccine incident" and the country to modify the corresponding regulations, adjust some vaccine policies, build a vaccine procurement model, in the short term on the company's performance impact, the second quarter of the year the largest decline, the full-year operating indicators decreased significantly year-on-year. In 2016, the company's total revenue was RMB446 million, of which RMB411 million was generated from autonomous vaccine products, down -11.73% YoY, while revenue from agent vaccine products was RMB2.94 million, down -98.24% YoY.
2017, the Second Class Vaccine Market returned to growth as the industry emerged from the shadows and a number of related policies were introduced. In 2017, the company's total revenue was 1.343 billion yuan, of which the revenue of autonomous vaccine products was 989 million yuan, up 140.84 percent year-on-year, and the revenue of agency vaccine products was 274 million yuan, up 9,231.67 percent year-on-year. Zhifei biological self-produced and self-sold global exclusive product AC-Hib triple vaccine is the company's most important growth point of profits, the company and Merca East company renewed the 23-price pneumonia vaccine, inactivated hepatitis A vaccine agent distribution contract, at the same time, four-price HPV vaccine also successfully obtained drug registration approval, so far, according to public information was informed that Mercedon's four-price HPV vaccine in 26 provinces (municipalities) level units have won the bid.
the first half of 2018, AC-Hib triple vaccine as a representative of independent product sales growth, maintain a good situation, with four-price HPV vaccine as the representative of the agent products have been in the domestic provincial units bid, sales continue to rise steadily. In the first half of 2018, the company expects net profit growth of 290% to 315%, or about 670 million to 713 million yuan.into large organisms: human rabies vaccine leader
into large organisms mainly take self-employed team-led, promoter-assisted marketing model. Under the requirements of the new regulations on vaccines, the sales method of the company's domestic distributors mainly through direct sales to the district and county-level Centers for Disease Control and Prevention, and forwarded by them to the vaccination terminals, the company's export products through foreign distributors for business development and sales services. Since the second half of 2016, the company's operations have been on track, with operating income of 1.030 billion yuan in 2016, up 9.14% YoY.
2017, the company actively adapts to the new vaccine management policy related regulatory requirements, fully consolidate brand awareness, strengthen the development of incremental markets, continuously optimize the marketing model, expand the sales force, in the first-tier cities have been fully covered on the basis of the integration of high-quality channels, continue to increase the coverage of the district and county CDC, broaden Market share, has been at all levels of the Centers for Disease Control and Prevention and the general recognition of the market, overseas sales market, the company has built a leading domestic international registration team, strengthen the product overseas market registration work, rabies vaccine completed registration in 23 countries, product export sales in 32 countries, enhance the company's international level and market competitiveness. In 2017, the company's operating income was 1.276 billion yuan, up 23.93 percent year-on-year.
mainly derived from the production and sale of human rabies vaccine, accounting for more than 90% of the company's total revenue. According to the data issued by the Central Prosecutor's Court, the largest market share of human rabies vaccines in 2017 was in large organisms, at 38.46 percent, with the second-highest share of living organisms at 21.50 percent. It is reported that the 2-1-1 procedure is one of the two post-exposure in-muscle vaccination procedures recommended by the WHO, and the rabies vaccine for large organisms is currently the only Chinese vaccine approved to use the procedure, the company's "human rabies vaccine" 2-1-1 immunization procedure "in 2010 to obtain the Drug Administration production approval, the subject of vaccination only need to visit the vaccination 3 times, compared with the current immunization procedures reduced by 2 visits, not only to ensure the immune effect but also greatly convenient for patients.Kantai Bio: Hepatitis B vaccine to maintain industry-leading
Kantai Bio's hepatitis B vaccine market time is earlier, market share for many years to maintain industry-leading, the remaining 3 vaccine products in late 2012 and 2013 on the market, market share growth faster.
the implementation of the 2016 Regulations on the Circulation and Vaccination of Vaccines, the mode of circulation of vaccine products has changed significantly. According to the changes in industry policy, the company actively adjusted the sales model, participated in the provincial public resources trading platform centralized procurement methods, obtained access to vaccine sales qualifications, and then directly sold to county-level disease prevention and control institutions; The company vigorously develop direct sales team and professional promoters, and actively expand product sales channels to ensure the company's vaccine products sales. In 2016, the company's vaccine revenue was 544 million yuan, up 22.42% YoY.
2017, the vaccine industry by the "Shandong vaccine incident" gradually eliminated the impact of the market gradually recovered, the industry's growth potential appears. Kantai Bio fully engaged in product bidding, promotion, sales work, to achieve steady growth in operating performance. In 2017, the company's vaccine revenue reached 1,159 million yuan, up 113.07 percent year-on-year, and sales of te4 seedlings (cellless white-cracked haemophilus influenzae haemophilus vaccine) increased 124.4 percent year-on-year. 08%, sales of Hib vaccine (Haemophilus influenzae type b combined vaccine) increased by 133.18% YoY, and sales of hepatitis B vaccine (recombinant hepatitis B vaccine (brewing yeast)) increased by 150.38% YoY.
the first half of 2018, the company stepped up sales promotion efforts, vaccine sales are good, especially the four-way vaccine sales increased significantly, resulting in a significant increase in operating income and net profit compared to the same period last year. Net profit is expected to grow by 280% to 310%, or about 268 million to 289 million yuan. Conclusion
The 13th Five-Year Plan for Biotechnology Innovation, released in 2017, mentions that key technologies and bottleneck technologies such as vaccine molecular design, multi-link multi-price design, engineering cell construction, antibody engineering optimization, new release systems and new preparations, large-scale separation preparation, and effect evaluation are key to accelerate the development of new vaccines, antibodies, blood products and other major biological products.
after the "Shandong vaccine incident" baptism, the vaccine industry has taken off. From the current data, China's four major vaccine enterprises are breaking a billion vaccine sales, rapid development momentum. The four major vaccine enterprises each have fist products in hand, each other have both competition and the strength of the leading market, hpV vaccine has become a hot market in recent times, we can foresee the next three years, China's vaccine market will usher in a bumper harvest. (Mi Net)